Filing Analysis
Marker Therapeutics stockholders approved a significant increase in authorized common stock from 30 million to 130 million shares. This 333% increase in authorized capital provides the company with substantial capacity for future equity raises, though it signals potential massive dilution for current shareholders.
🚩 Red Flags
- Massive 333% increase in authorized shares suggests significant impending dilution for existing shareholders.
- Failure of Proposal 4 indicates shareholder resistance to lowering the threshold for future share count adjustments.
📋 Key Facts
- Stockholders approved an amendment to the Certificate of Incorporation to increase authorized common stock from 30,000,000 to 130,000,000 shares.
- Proposal 4, which sought to revise the voting threshold required for future increases or decreases of common stock, failed to pass.
- CBIZ CPAs P.C. was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
- Five directors (David Eansor, Steven Elms, Katharine Knobil, Juan Vera, and Kathryn Penkus Corzo) were re-elected to the board.
- As of the record date, 16,673,127 shares were outstanding, with 74.24% representation at the meeting.
Marker Therapeutics reported its financial results for the fiscal year ended December 31, 2025, and provided recent corporate updates. The information was furnished via a press release attached as Exhibit 99.1.
📋 Key Facts
- Reported financial results for the full year ended December 31, 2025, on March 18, 2026.
- The filing was made under Item 2.02 (Results of Operations and Financial Condition).
- The report includes corporate updates in addition to financial data.
- The information is furnished and not deemed 'filed' for purposes of Section 18 of the Securities Exchange Act of 1934.
Marker Therapeutics, Inc. has announced the scheduling of its 2026 Annual Meeting of Stockholders for May 1, 2026. Due to the meeting date being advanced by more than 30 days from the anniversary of the previous year's meeting, a new deadline for stockholder proposals has been established.
📋 Key Facts
- The 2026 Annual Meeting of Stockholders is scheduled for May 1, 2026.
- Stockholder proposals intended for inclusion in the proxy statement must be received by March 9, 2026.
- The meeting date change was made in accordance with Rule 14a-18 under the Securities Exchange Act of 1934.
Marker Therapeutics, Inc. filed an 8-K to report its financial results for the third quarter ended September 30, 2025. The filing serves as a formal announcement of quarterly earnings and recent corporate updates.
📋 Key Facts
- Reporting period: Third Quarter ended September 30, 2025.
- Filing date: November 14, 2025.
- The company reported results via a press release furnished as Exhibit 99.1.
Marker Therapeutics, Inc. announced the appointment of Kathryn Penkus Corzo to its Board of Directors and a discretionary stock option award for CEO Dr. Juan Vera.
📋 Key Facts
- Kathryn Penkus Corzo appointed to the Board effective November 1, 2025.
- Ms. Corzo granted 147,611 stock options vesting evenly over 36 months.
- CEO Dr. Juan Vera granted a discretionary award of 250,000 stock options on October 31, 2025.
- The CEO options vest annually over four years.
Marker Therapeutics announced the successful treatment of the first patient in its Off-the-Shelf (OTS) Program involving MAR-T cell therapy. This represents a clinical milestone for the company's therapeutic pipeline.
📋 Key Facts
- First patient treated in the Company’s Off-the-Shelf (OTS) Program.
- The program evaluates Marker’s Multi-Antigen Recognizing (MAR)-T cell therapy.
- Announcement date: October 6, 2025.
Marker Therapeutics, Inc. issued an 8-K to announce clinical progress from its Phase 1 APOLLO study and updated its corporate presentation. The company also scheduled a webcast to discuss the study results.
📋 Key Facts
- Announced clinical observations from the Phase 1 APOLLO study on August 26, 2025.
- Updated the Company's corporate presentation.
- Scheduled a webcast to discuss the APOLLO study results.
- Filed under Item 7.01 (Regulation FD Disclosure) and Item 9.01 (Financial Statements and Exhibits).
Marker Therapeutics, Inc. has replaced its independent auditor, Marcum LLP, with CBIZ CPAs P.C., effective immediately for the review of Q2 2025 financial statements. The filing notes that previous audits contained going concern warnings.
🚩 Red Flags
- Going concern language: Previous audits (2023, 2024) contained explanatory paragraphs regarding substantial doubt about the ability to continue as a going concern.
- Auditor change combined with existing going concern uncertainty is a high-risk signal for micro-cap companies.
📋 Key Facts
- Marcum LLP resigned as the Company's independent registered public accounting firm on August 6, 2025.
- CBIZ CPAs P.C. has been engaged to serve as the new independent auditor for the fiscal year ending December 31, 2025.
- The change is effective beginning with the review of condensed consolidated financial statements for the quarter ended June 30, 2025.
- Marcum's previous reports for 2023 and 2024 included an explanatory paragraph regarding substantial doubt about the Company's ability to continue as a going concern.
- The company stated there were no disagreements with Marcum regarding accounting principles or auditing procedures.
Marker Therapeutics entered into a Statement of Work (SOW) with Cellipont Bioservices to support the manufacturing and scale-up of its lead MT-601 MAR-T cell therapy. The agreement focuses on technology transfer and cGMP manufacturing services for the company's APOLLO study over a nine-month period.
📋 Key Facts
- Entered into a Statement of Work (SOW) with Cellipont Bioservices, a CDMO.
- Purpose: Technology transfer and cGMP manufacturing for lead candidate MT-601.
- Objective: Support scale-up and production for the APOLLO study.
- Timeline: The SOW outlines technology transfer processes over the next nine months.
Marker Therapeutics, Inc. held its 2025 Annual Meeting of Stockholders on June 6, 2025. The meeting resulted in the successful election of four directors, advisory approval of executive compensation, and ratification of Marcum LLP as the independent auditor.
📋 Key Facts
- Annual Meeting held on June 6, 2025.
- Quorum reached with 7,629,048 shares (67.43%) present or represented out of 11,314,835 total shares outstanding.
- Four nominees elected to the Board: David Eansor, Steven Elms, Katharine Knobil, and Juan Vera.
- Advisory 'Say-on-Pay' proposal for executive compensation was approved (4,449,829 votes in favor).
- Ratification of Marcum LLP as independent registered public accounting firm for fiscal year ending Dec 31, 2025, was approved.
Marker Therapeutics issued a press release regarding positive Phase 1 study data for its lead product, MT-601. The data suggests that lymphodepletion enhances the expansion and persistence of Multi-Antigen Recognizing-T Cells in lymphoma patients.
📋 Key Facts
- Company released clinical update on lead product MT-601 via press release dated May 20, 2025.
- Phase 1 study data indicates lymphodepletion improves expansion and persistence of Multi-Antigen Recognizing-T Cells in lymphoma patients.
Marker Therapeutics, Inc. filed an 8-K to report its financial results for the fiscal year ended December 31, 2024. The filing serves as a formal announcement of annual earnings and recent corporate updates.
📋 Key Facts
- Reported financial results for the fiscal year ended December 31, 2024.
- The report includes other recent corporate updates via an attached press release (Exhibit 99.1).
- Filed on March 31, 2025.
Marker Therapeutics held a Special Meeting of Stockholders on March 21, 2025, where shareholders approved the issuance of shares issuable upon the exercise of Series A and Series B warrants. This approval was required to comply with Nasdaq Listing Rule 5635(d) regarding the issuance of common stock.
🚩 Red Flags
- Significant potential dilution: The warrants represent over 80% of the existing shares outstanding (8,278,695 total issuable shares vs. 10,709,005 current shares).
- Requirement for Nasdaq Rule 5635(d) approval often implies a prior breach or potential breach of the 'change in control' or 'issuance of warrants' rules, which can be a sign of distressed financing.
📋 Key Facts
- Special Meeting held on March 21, 2025.
- Proposal 1: Approval of issuance of shares via Series A Warrants (5,031,250 shares) and Series B Warrants (3,247,445 shares).
- Total shares outstanding as of record date: 10,709,005.
- Quorum/Participation: 4,158,543 shares (38.83%) were present or represented by proxy.
- Voting Result for Proposal 1: 3,483,897 votes 'For', 668,383 votes 'Against', and 6,263 'Abstained'.
- The approval was necessary to satisfy Nasdaq Listing Rule 5635(d).
This is an Amendment No. 1 to a previously filed 8-K, issued to correct a clerical error regarding the grant dates of stock options for the CEO and Non-Employee Directors. The filing corrects the year from 2024 to 2025 for awards granted on February 12.
🚩 Red Flags
- Clerical error in previous SEC filing regarding equity grant dates.
📋 Key Facts
- The filing is an amendment (8-K/A) to a report originally filed on February 19, 2025.
- Corrects the grant date of stock options from February 12, 2024, to February 12, 2025.
- CEO Dr. Juan Vera was awarded 50,000 stock options vesting annually over three years.
- Three Non-Employee Directors (David Eansor, Katherine Knobil, and Steven Elms) were each awarded 30,000 stock options vesting annually over three years.
Marker Therapeutics, Inc. filed an 8-K reporting the approval of discretionary stock option awards for its CEO and three Non-Employee Directors.
🚩 Red Flags
- None identified in this filing.
📋 Key Facts
- On February 12, 2024, the Board approved a discretionary award of 50,000 stock options to CEO Dr. Juan Vera.
- The CEO Options vest annually over a three-year period starting from the grant date.
- On February 12, 2024, the Board approved awards of 30,000 stock options each to Non-Employee Directors David Eansor, Katherine Knobil, and Steven Elms.
- Director options also vest annually over a three-year period.
Marker Therapeutics, Inc. announced the resignation of John Wilson from its Board of Directors effective January 24, 2025.
📋 Key Facts
- John Wilson resigned from the Board of Directors on January 24, 2025.
- The resignation was reported via an 8-K filed on January 30, 2025.
Marker Therapeutics, Inc. closed a $16.1 million private placement of common stock and warrants on December 23, 2024. The offering includes significant potential dilution through various warrant classes and requires stockholder approval for certain issuances.
🚩 Red Flags
- Significant potential dilution from over 8.3 million total shares issuable via warrants (Series A and Pre-Funded).
- Requirement for recurring stockholder meetings if approval is not obtained within the specified timeframe.
- Heavy reliance on private placement to fund general corporate purposes and working capital, typical of cash-strapped micro-caps.
📋 Key Facts
- Closed a private placement on December 23, 2024, raising approximately $16.1 million in gross proceeds.
- Issued 1,783,805 shares of Common Stock.
- Issued Series A Warrants to acquire 5,031,250 shares of Common Stock at an exercise price of $4.00 per share.
- Issued partially prepaid warrants (Pre-Funded Warrants) to acquire 3,248,445 additional shares of Common Stock at an exercise price of $0.001 per share.
- Company must obtain stockholder approval for the issuance of shares upon exercise of the Warrants within 90 days; failure to do so triggers recurring semi-annual meetings.
- Certain stockholders representing ~27% of common stock have entered into voting agreements to support the private placement.
- Registration Rights Agreement requires filing a registration statement by January 14, 2025.
Marker Therapeutics entered into a securities purchase agreement for a private placement expected to raise $16.1 million in gross proceeds. The offering involves the sale of 5,031,250 shares/pre-funded warrants at $3.20 per share and includes accompanying warrants with an exercise price of $4.03.
🚩 Red Flags
- Significant potential dilution: The issuance of over 5 million shares plus warrants represents a substantial increase in share count.
- Warrant overhang: Accompanying warrants at $4.03 represent a price premium, but the scale of total possible shares (up to ~10M) is significant for a micro-cap.
📋 Key Facts
- Private placement expected to provide $16.1 million in gross proceeds before fees.
- Sale of 5,031,250 shares of common stock (or pre-funded warrants) at $3.20 per share.
- Accompanying warrants to purchase up to 5,031,250 shares at an exercise price of $4.03 per share.
- Pre-funded warrants have a term of five years upon shareholder approval.
- Transaction expected to close on December 23, 2024.
- Includes registration rights agreement and voting agreements with certain shareholders.
Marker Therapeutics, Inc. announced it has been awarded a $9.5 million grant from the Cancer Prevention & Research Institute of Texas (CPRIT). The funds are designated to support clinical investigation of MT-601 for pancreatic cancer patients.
📋 Key Facts
- Award amount: $9.5 Million
- Grantor: Cancer Prevention & Research Institute of Texas (CPRIT)
- Purpose: Clinical investigation of MT-601 in pancreatic cancer patients
- Announcement Date: December 17, 2024
Marker Therapeutics, Inc. filed an 8-K to report its financial results for the quarter ended September 30, 2024, and provided other recent corporate updates via a press release.
📋 Key Facts
- Reported financial results for the fiscal quarter ended September 30, 2024.
- Filing date: November 14, 2024.
- The report includes an updated press release as Exhibit 99.1.
Marker Therapeutics, Inc. filed an 8-K to report its financial results for the quarter ended June 30, 2024. The filing serves as a formal announcement of recent corporate updates and quarterly performance.
📋 Key Facts
- Reported financial results for the quarter ended June 30, 2024.
- Filed on August 14, 2024.
- The report includes a press release as Exhibit 99.1.
Marker Therapeutics announced it has been awarded a $2 million grant from the NIH SBIR program. The funds are designated to support clinical investigation of MT-601 for patients with relapsed non-Hodgkin’s lymphoma following CAR T cell therapy.
📋 Key Facts
- Awarded a $2 million grant from the National Institutes of Health (NIH) Small Business Innovation Research (SBIR) program.
- Grant purpose: Clinical investigation of MT-601 in patients with non-Hodgkin’s lymphoma (NHL).
- Target patient population: Patients who have relapsed following anti-CD19 chimeric antigen receptor (CAR) T cell therapy.
- Announcement date: August 12, 2024.
Marker Therapeutics held its 2024 Annual Meeting of Stockholders on June 6, 2024, where all director nominees and advisory compensation proposals were approved. Additionally, the company terminated an At-the-Market (ATM) equity offering agreement with Cantor Fitzgerald & Co. and RBC Capital Markets.
🚩 Red Flags
- Termination of an ATM program can sometimes indicate a strategic shift or a desire to avoid potential dilution/market signaling, though here it is noted as penalty-free.
📋 Key Facts
- Annual Meeting held on June 6, 2024; quorum reached at 63.35% of outstanding shares.
- Five directors elected: David Eansor, Steven Elms, John Wilson, Juan Vera, and Katharine Knobil.
- Advisory approval of named executive officer compensation was passed (2,931,920 votes for).
- Ratification of Marcum LLP as independent auditor for FY 2024 was approved.
- Termination of a $75.0 million Controlled Equity Offering SM Sales Agreement (ATM Program) effective June 10, 2024.
- No termination penalties were incurred for the cancellation of the ATM agreement.
Marker Therapeutics, Inc. filed an 8-K to report its financial results for the quarter ended March 31, 2024 and provided other recent corporate updates.
📋 Key Facts
- Reported financial results for the fiscal quarter ended March 31, 2024.
- The filing includes a press release dated May 15, 2024 as Exhibit 99.1.
- The information under Item 2.02 is furnished but not filed for purposes of Section 18 of the Exchange Act.
Marker Therapeutics announced that Principal Investigator Dr. Geoffrey Shouse presented clinical observations from the APOLLO study at a global hematologic malignancies summit. The presentation highlighted positive early data regarding dose tolerance and durable objective responses for MT-601 treatment.
📋 Key Facts
- Dr. Geoffrey Shouse (City of Hope) presented clinical experience from the APOLLO study on April 6, 2024.
- Presentation occurred at the 11th Global Summit on Hematologic Malignancies in Whistler, BC.
- Clinical observations reported that participants tolerated initial dose levels well.
- Reported durable objective responses were observed following MT-601 treatment.
Marker Therapeutics, Inc. filed an 8-K to report its financial results for the fiscal year ended December 31, 2023, and provided other recent corporate updates via a press release.
📋 Key Facts
- Reported financial results for the fiscal year ended December 31, 2023.
- The filing includes an update on 'other recent corporate updates' as of March 25, 2024.
- Financial information is provided in Exhibit 99.1 via a press release.
Marker Therapeutics has terminated a $25 million purchase agreement with Lincoln Park Capital Fund, LLC effective March 1, 2024. The company states it has sufficient liquidity to fund operations through Q4 2025 and does not require immediate capital.
🚩 Red Flags
- Termination of a significant capital source ($25M) could be viewed negatively if cash burn exceeds projections.
- Minimal utilization of the purchase agreement (only $33k in proceeds from a $25M facility) suggests the financing was largely unused or ineffective.
📋 Key Facts
- Termination of Purchase Agreement with Lincoln Park Capital Fund, LLC (LPC) effective March 1, 2024.
- The terminated agreement allowed for the sale of up to $25 million in common stock over a 24-month term.
- Company projects a financial runway through the fourth quarter of 2025.
- Only 12,500 shares were sold under the agreement, generating approximately $33,000 in proceeds.
- The company had previously issued 1,804,098 Commitment Shares to LPC as consideration for entering the agreement.
Marker Therapeutics entered into a Master Services Agreement with Cell Ready LLC, a CDMO owned by Director and Shareholder John Wilson. The agreement includes an initial work order for GMP drug product manufacturing for MT-401/MT-601 not to exceed $750,000.
🚩 Red Flags
- Related-party transaction: The service provider (Cell Ready LLC) is owned by an existing director and shareholder of the company.
📋 Key Facts
- Entered into Master Services Agreement with Cell Ready LLC on February 22, 2024.
- Cell Ready is owned by Mr. John Wilson, a director and shareholder of Marker Therapeutics.
- Work Order #1 covers GMP drug product for MT-401 and/or MT-601 including quality control testing.
- The projected sum for Work Order #1 is not anticipated to exceed $750,000.
- The agreement term is three years with a 30-day cure period for material breaches.
Marker Therapeutics announced management's participation in the Biotech Showcase and the 19th Annual Non-Dilutive Funding Summit during J.P. Morgan Healthcare Conference week. The filing also notes a press release regarding clinical program updates and pipeline prioritization.
🚩 Red Flags
- The mention of 'Pipeline Prioritization' can sometimes imply the discontinuation or scaling back of certain R&D programs due to capital constraints, though specific details are in the referenced press release (not fully provided).
📋 Key Facts
- CEO Juan Vera will participate in the Biotech Showcase at the 19th Annual Non-Dilutive Funding Summit.
- The summit is held alongside the 42nd Annual J.P. Morgan Healthcare Conference 2024.
- Company issued a press release on January 8, 2024, regarding Clinical Program Updates and Pipeline Prioritization.
- Updated corporate presentation was released for investor/analyst meetings.